G01N 2800/16
Ophthalmology
G01N2800/16 (Ophthalmology) appears on 187 US grants and 469 published applications in this corpus.
Search patents in G01N- Granted patents
- 187
- Published applications
- 469
- Assignees
- 253
- Inventors
- 863
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 4 |
| 2003 | 0 | 6 |
| 2004 | 1 | 7 |
| 2005 | 1 | 12 |
| 2006 | 4 | 16 |
| 2007 | 2 | 10 |
| 2008 | 4 | 16 |
| 2009 | 0 | 21 |
| 2010 | 7 | 26 |
| 2011 | 8 | 26 |
| 2012 | 10 | 24 |
| 2013 | 11 | 10 |
| 2014 | 8 | 26 |
| 2015 | 13 | 33 |
| 2016 | 6 | 16 |
| 2017 | 8 | 22 |
| 2018 | 7 | 26 |
| 2019 | 11 | 15 |
| 2020 | 11 | 30 |
| 2021 | 11 | 27 |
| 2022 | 10 | 26 |
| 2023 | 15 | 27 |
| 2024 | 10 | 20 |
| 2025 | 11 | 12 |
| 2026 | 8 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition15 Sep 2026US 12,735,707 B2Massachusetts Eye and Ear Infirmary
- Anti-VEGF single-domain antibody and use thereof16 Jun 2026US 12,655,204 B2Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Amino acid, organic compound and oxylipidin biomarkers in blood for macular edema and use thereof16 Jun 2026US 12,656,352 B2Konkuk University Industrial Cooperation Corp.
- Methods for diagnosing and treating uveitis19 May 2026US 12,631,653 B2The Board of Trustees of the Leland Stanford Junior University
- Prediction of the content of omega-3 polyunsaturated fatty acids in the retina by measuring 7 cholesterol ester molecules7 Apr 2026US 12,596,127 B2Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Use of extracellular vesicles as biomarkers for age-related macular degeneration27 Aug 2026US 2026/0250766 A1Research Foundation of the City University of New York
- Methods for monitoring molecular biomarkers for aging and disease27 Aug 2026US 2026/0251662 A9The Board of Trustees of the Leland Stanford Junior University
- Cd59 for inhibiting inflammasome activation13 Aug 2026US 2026/0232845 A1Trustees of Tufts College
- Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders16 Jul 2026US 2026/0199341 A1Children's Medical Center Corporation
- Methods for selecting and treating patients with retinal disease based on complement pathway hyperactivity2 Jul 2026US 2026/0185992 A1Oak Bay Biosciences Inc.
Most cited
By later US patents
- Compositions and methods for treatment of eye disorders84US 8,168,655 B2Sarcode Bioscience Inc. · 2012
- Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration46US 7,816,497 B2University of Kentucky · 2010
- Diagnostics and the therapeutics for macular degeneration33US 7,108,982 B1University of Iowa Research Foundation · 2006
- Compositions and methods for treatment of eye disorders29US 8,084,047 B2Sarcode Bioscience Inc. · 2011
- Diagnostics and therapeutics for macular degeneration-related disorders28US 7,351,524 B2University of Iowa Research Foundation · 2008